RE:RE:RE:RE:RE:RE:RE:DM- expirations of optionsHey trussell, not sure that I'm sensing the anger that you apparently sense and as far as bagholders go I'm sure there are many longtermers here like me that do fewer trades but were strong buyers when the price was very cheap and as such are still well in the money even at the current price. I sold a very small part of my position a couple of months ago at a great profit but am mostly looking at exits further down the road. Good for you on your trades though. I agree that management could be better (sometimes a lot better) but I have said for a number of years on this board. I feel that part of the risk assessment with an investment in RVX has always been whether or not great science could win out over mediocre management. Believed it back then and still believe it now. That being said though I think as we move forward that strength of the science more and more overshadows the weakness of management. In the end I don't think it will matter whether it's DM or Donald Duck in the CEO chair, if ph3 is successful pharmas will be buyers and the big investors here will be looking for a big price.
WRT ph3, I think that a lot of people here don't understand that even if RVX does not get ph3 trial approval from the FDA it doesn't mean that the FDA will not look at the trial results. No FDA trial approval just means no U.S. trial sites. The recent 21st Century Cures legislation in the U.S. is aimed exactly at the FDA looking at marketing approval for drugs where the trials have been conducted at exU.S. sites. Of course it would be great for the SP to get the FDA trial approval.
Might also be great for SP to see some serious analyst days and get serious analyst coverage. Additionally, perhaps do a share consolidation and get a NASDAQ listing if an FDA trial approval is achieved. But these are management issues so not holding my breath.